Post-2028 Transition of Russian Registration Portfolios to Union Rules
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Existing Russian national registration certificates do not lapse after 2028: the validity of the rules of Decision No. 1684 has been extended to 31 December 2028, and variation applications submitted before that deadline are still processed under the national rules; meanwhile, new applications from 1 January 2028 can only be filed under the Union rules. The result is a pattern of existing certificates remaining manageable while new volume switches tracks. A portfolio that mixes old and new products therefore runs two regulatory tracks simultaneously, each with its own obligations, timelines and documentation standards.
The practical consequence is that the year 2027 becomes the pivot year. Variations that a company knows it will need should be brought forward and submitted under the national rules before 31 December 2028, while evidence packages for any product that will need a Union application must be built to Union depth during 2027. Companies that treat 2028 as a distant deadline typically discover in the second half of 2027 that expert organisations, laboratories and authorised representatives are fully booked.
The ratification step also deserves monitoring rather than assumption. The Protocol was signed on 29 December 2025 and ratified by the Russian side through Federal Law No. 288-FZ of 4 August 2026, and the checklist of transition planning should record whether the Protocol applies provisionally or is already in force at the time of each decision, because the applicability status determines which timetable governs a specific application. Re-checking that status at each planning round is a five-minute task that prevents a systematically wrong schedule.
2. Legal basis
The transition architecture is defined by the extension of the national rules, the protocol amending the 2014 agreement and its ratification, and the Union rules that apply to new applications after 2028. The instruments are summarised below.
| Instrument | Number | Date | Provisions |
|---|---|---|---|
| Government Decision of the Russian Federation (extending the validity of Decision No. 1684) | ПП РФ No. 2214 | 30 December 2025 (in force 2026-01-08) | the rules remain in force until 2028-12-31 |
| Protocol amending the 2014 Agreement | Protocol | signed 29 December 2025 | Article 11: new applications until 2027-12-31, variations until 2028-12-31 |
| Federal Law of the Russian Federation (ratifying the Protocol) | 288-FZ | 4 August 2026 | ratification by the Russian side |
| Decision of the Eurasian Economic Commission on registration and expert review rules | EEC Decision No. 46 | 12 February 2016 | the rules applicable to new applications after 2028 |
3. Expert insights
Insight 1: existing certificates and new volume must be managed in separate registers. The compliance actions for existing certificates — variations, monitoring, marking — can continue under the national rules until the end of 2028, while the path for new products switches to the Union rules from the beginning of 2028, since new applications from 1 January 2028 can only be submitted under the Union rules. The two registers carry different checklists, and merging them is the most common source of missed deadlines in a transition portfolio: an action planned on the national timetable but executed against a Union requirement, or the reverse.
Insight 2: switching tracks is in substance an upgrade of the dossier. The evidentiary depth demanded by the Union path is higher than that of the national path: the quality management system (in the direction of EEC Decision No. 106), biological evaluation (in the direction of Decision No. 38), and communication with reference countries and recognised countries all have to be prepared in advance. The gap analysis between the existing national dossier and the Union evidence package should be run early, because some evidence — particularly biological evaluation data — has long lead times that no amount of late scheduling can compress.
Insight 3: the Union path is not opening only in 2028. Choosing to move to the Union path early, within the window still available, avoids the concentrated queue at the end of 2027 and makes it easier to position in several member states at once. For portfolios with genuine multi-country ambitions, the Union route is not only a compliance necessity after 2028 but also an efficiency choice before it: one application, several markets, and a single evidence standard maintained thereafter.
4. Practical recommendations
The recommendations below separate the maintenance workload from the transition workload, which is the core of transition planning.
- Establish dual registers for existing certificates and for new volume, and schedule preliminary studies of the Union path for every incremental product, so that the 2028 switch does not arrive as a surprise.
- Execute the evidence preparation planned for 2027 at Union depth, so that one investment of effort serves both the national maintenance and the future Union application.
- For products serving only the single Russian market with no successor models planned, maintain them under the national rules until 2028 — a Union application would be investment without a return.
- Bring forward to 2027 the variations that are already foreseeable for 2028, and track the submission dates in the register rather than in individual memories.
5. Verification checklist
The checklist below confirms that the portfolio is split, scheduled and evidenced for the transition.
- □ The portfolio has been split into two registers: maintenance of existing certificates and transition of new volume
- □ Variations planned for 2028 have been brought forward to begin in 2027
- □ The evidence gaps for the Union path — QMS, biological evaluation and related items — have been assessed
- □ The reference country scheme for multi-member-state market plans has been determined
- □ The applicability status of the Protocol (provisional application / in force) has been re-checked
- □ The date 2028-12-31 as the close-out deadline for existing certificate variations is recorded in the register
Regulatory information verified as of 29 October 2026.
GRZAN advises manufacturers on the post-2028 transition of their Russian portfolios, including dual-track register design, gap analysis against Union evidence requirements, reference country selection and variation scheduling ahead of the 31 December 2028 close-out, together with post-market vigilance, recall and inspection support. For transition planning assistance, contact us at info@grzanglobal.com.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us